Mucormycosis

Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022

Retrieved on: 
Wednesday, October 12, 2022
RNA transfection, Adult, Pharmacist, National, Walter, Society of Infectious Diseases Pharmacists, Infectious Diseases Society of America, University of Minnesota, DNA, Solution, Epidemiology, Enactment, NYSE, MPH, Makerere University, Amphotericin B, Private Securities Litigation Reform Act, Company, LNC, Mycosis, PIDS, Cryptococcosis, GLOBE, Consultant, Hoffmann-La Roche, Amikacin, Infectious Diseases Institute, Diagnosis, Vaccine, Walter E. Washington Convention Center, Research, Gilead Sciences, Technology, BioNTech, HIV, Organic acid, IDSA, ID, Form 10-K, Washington Convention Center, Risk, Physician, Sale, Harbor–UCLA Medical Center, SEC, ABC, Patient, Infection, Partnership, Society, Abstract (summary), Forward-looking statement, Mucormycosis, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery, Genentech, MD

BEDMINSTER, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform delivery technology, today announced three upcoming oral data presentations during IDWeek 2022, the premier U.S. meeting of leaders in the field of infectious diseases taking place in-person at the Walter E. Washington Convention Center, in Washington DC from October 19-23, 2022.

Key Points: 
  • The data from these three presentations provide a deeper understanding of MAT2203s safety profile and impressive efficacy against two of the deadliest invasive fungal infections in cryptococcal meningitis and mucormycosis, said Theresa Matkovits, Ph.D., Chief Development Officer of Matinas BioPharma .
  • Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology.
  • The Company is focused on developing an internal and external pipeline of drugs candidates based on the LNC platform.
  • Matinas BioPharmas product candidates are all in a development stage and are not available for sale or use.

Innovation Pharmaceuticals Announces Publication of Scientific Article on the Antifungal Activity of Brilacidin

Retrieved on: 
Tuesday, October 4, 2022
OTCQB, CAS, Â, Brilacidin, GLOBE, Mucormycosis, Toxicity, Cryptococcus neoformans, Mycosis, Mortality, Human, Review, Mycology, Cryptococcus, Research, Disease, Cryptococcosis, Aspergillosis, Antifungal, Patent, 50, Calcineurin, VOR, Caspofungin, Drug resistance, Molecular biology, Candidiasis, Orphan drug, William DeGrado, Aspergillus fumigatus, Patient, Voriconazole, POSA, Canker, Preprint, University, HIV/AIDS, Pharmaceutical industry, Vaccine, Aspergillus, Mucorales

A Host Defense Peptide Mimetic, Brilacidin, Potentiates Caspofungin Antifungal Activity Against Human Pathogenic Fungi.

Key Points: 
  • A Host Defense Peptide Mimetic, Brilacidin, Potentiates Caspofungin Antifungal Activity Against Human Pathogenic Fungi.
  • Following an in vitro drug screening of 1,402 compounds, Brilacidin showed promising antifungal activity and was subsequently selected for additional pre-clinical evaluation, including in combination with caspofungin (CAS), voriconazole (VOR), and posaconazole (POSA), all current antifungal treatments.
  • Further in vitro testing showed Brilacidin synergized with CAS in C. albicans, C. auris and C. neoformans.
  • Pivotal clinical trials for antifungal drugs are generally smaller than those in other infectious disease areas, requiring between 300 and 600 patients.

Matinas BioPharma Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for MAT2203 for the Treatment of Cryptococcosis

Retrieved on: 
Monday, July 25, 2022
DNA, Sale, National, Diagnosis, GLOBE, Toxicity, Consultant, Committee, Tissue, Food, Orphan, Forward-looking statement, SEC, NYSE, COMP, Research, Risk, EMA, Royal commission, Solution, Private Securities Litigation Reform Act, Mucormycosis, Cryptococcosis, Hoffmann-La Roche, Partnership, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LNC, RNA transfection, Form 10-K, Mycosis, Canker, Amikacin, European Commission, European Medicines Agency, Technology, Disease, FDA, Company, Gilead Sciences, Patient, BioNTech, JN-International Medical Corporation, QIDP, Prevalence, Vaccine, Organic acid, Pharmaceutical industry, EU, Genentech

The U.S. Food and Drug Administration (FDA) previously granted Orphan, Qualified Infectious Disease Product (QIDP) and Fast Track Designations to MAT2203 for the treatment of cryptococcosis.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) previously granted Orphan, Qualified Infectious Disease Product (QIDP) and Fast Track Designations to MAT2203 for the treatment of cryptococcosis.
  • Matinas is currently preparing to evaluate MAT2203 in a pivotal Phase 3 trial in patients with cryptococcal meningitis.
  • The positive opinion for Orphan Drug Designation from the EMA is another important milestone for MAT2203 and reflects our commitment to position MAT2203 for global development and approval, said Theresa Matkovits, Ph.D., Chief Development Officer of Matinas BioPharma.
  • We believe that MAT2203 has the potential to transform the treatment of cryptococcosis, as well as other deadly invasive fungal infections.

Cresemba® sales in Asia Pacific region trigger sales milestone payment to Basilea from Pfizer

Retrieved on: 
Friday, June 17, 2022
Cancer, I.V. (X Japan song), Mortality, Infection, Mucormycosis, Lymphatic system, Azole, Immunodeficiency, Research, SIX Swiss Exchange, Growth, Disease, USD, PFE, Adult, Patient, Communication, NYSE, CHF, Mycosis, Pharmaceutical industry, Isavuconazonium, Pfizer, Basel, EU

Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today that the sales of the antifungal Cresemba (isavuconazole) by its license partner Pfizer Inc. (NYSE: PFE, Pfizer) in the Asia Pacific region, exceeded the threshold triggering the first sales milestone payment for this region of USD 1.25 million.

Key Points: 
  • Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today that the sales of the antifungal Cresemba (isavuconazole) by its license partner Pfizer Inc. (NYSE: PFE, Pfizer) in the Asia Pacific region, exceeded the threshold triggering the first sales milestone payment for this region of USD 1.25 million.
  • David Veitch, Basileas Chief Executive Officer, stated: We are very pleased with the commercial progress of Cresemba, which has now triggered the first sales milestone payment from Pfizer for the Asia Pacific region.
  • The license agreement between Basilea and Pfizer for Cresemba covers Europe (excluding the Nordic countries) as well as countries in the Asia Pacific region and China.
  • Under the agreement with Pfizer, Basilea is eligible for additional regulatory and sales milestone payments of up to around CHF 550 million, in addition to receiving mid-teen royalties on sales.

SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 12, 2022
Infection, Auris, Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Survival, EDT, Posaconazole, POSA, Candida auris, Fluconazole, Patient, NASDAQ, Drug of last resort, European, IV, Prescription, Data, BID, FDA, Mycosis, Mouse, Recurrence, Commercial, Biotechnology, FURI, Congress, NDA, LAMB, Tablet, Candidiasis, Headache, Mucormycosis, Fungemia, HCPS, GLOBE, Pharmaceutical industry, Insurance, Medical device, IQVIA, VVC

SCYNEXIS will host a conference call today, May 12 at 8:30 a.m. EDT

Key Points: 
  • SCYNEXIS will host a conference call today, May 12 at 8:30 a.m. EDT
    JERSEY CITY, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the first quarter ended on March 31, 2022.
  • Research and development expense for the first quarter of 2022 decreased to $5.7 million from $6.9 million versus the first quarter of 2021.
  • Selling, general & administrative (SG&A) expense for the first quarter of 2022 increased to $14.6 million from $6.7 million versus the first quarter of 2021.
  • Total other income was $9.6 million for the first quarter of 2022, versus total other expense of $2.0 million for the first quarter of 2021.

SCYNEXIS Presents Data Analyses Showing Ibrexafungerp’s Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases

Retrieved on: 
Wednesday, April 27, 2022
Patient, Treatment, Biotechnology, COVID-19, Mucormycosis, NASDAQ, Research, European, Infection, LAMB, GLOBE, POSA, Drug of last resort, Mortality, Congress, FURI, Candida auris, Fungemia, Auris, HIV disease progression rates, Disease, Posaconazole, Mycosis, Interim, Survival, Pharmaceutical industry, Medical imaging

The posters were presented at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) held in Lisbon, Portugal April 23-26, 2022.

Key Points: 
  • The posters were presented at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) held in Lisbon, Portugal April 23-26, 2022.
  • We are excited to share these latest data with the medical community as we advance our hospital clinical programs in invasive candidiasis, including candidemia, said David Angulo, M.D.
  • Ibrexafungerp is in late-stage investigation and development for multiple indications, including life-threatening fungal infections caused primarily by Candida (including C. auris) and Aspergillus species in hospitalized patients.
  • In addition, late-stage clinical investigation of oral ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (VVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing.

SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 29, 2022
Candidiasis, Overalls, Biotechnology, Research, European Medicines Agency, TIMM, Commercial, Prescription, Fluconazole, IC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, NDA, IV, Recurrence, Greater, Sale, FURI, Trial of the century, Mucormycosis, CMC, EDT, Shanda, New Drug Application, NIH, Chemistry, EMA, Income, HCPS, Amphotericin B, Headache, NASDAQ, Patent, Growth, Pharmacokinetics, Mortality, Survival, Tablet, Virtual, VVC, Information technology, BID, FDA, Patient, Infection, Company, Medical Mycology, Drug of last resort, SG, Food, Safety, Ridesharing company, Insurance, Pharmaceutical industry, Perfume, Video game, IQVIA, EU

Based on cash balance at December 31, 2021 and operating plan, SCYNEXIS has a projected cash runway into the second quarter of 2023.

Key Points: 
  • Based on cash balance at December 31, 2021 and operating plan, SCYNEXIS has a projected cash runway into the second quarter of 2023.
  • BREXAFEMME delivered $0.6 million in net sales in fourth quarter 2021 and $1.1 million in total net sales in 2021.
  • Research and development expense for the fourth quarter of 2021 decreased to $7.7 million from $10.2 million versus the fourth quarter of 2020.
  • Selling, general& administrative (SG&A) expense for the fourth quarter of 2021 increased to $15.0 million from $5.2 million versus the fourth quarter of 2020.

Matinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

Retrieved on: 
Tuesday, March 8, 2022
Form 10-K, Cryptococcosis, Allergy, Enrollment, LNC, Cohort, Infection, Nucleic acid, Degenerative disease, University of North Carolina at Greensboro, Science, Chapel Hill, Cystic fibrosis, Partnership, Auris, Private Securities Litigation Reform Act, Vaccine, Necessity and sufficiency, Forward-looking statement, Organic acid, European Medicines Agency, FDA, Solution, SEC, Company, Consultant, National Institute, Clinical trial, NTM, Enactment, EPA, Candida auris, Department, Investor, Food, NIAID, EMA, Hand, NYSE, Cystic Fibrosis Foundation, Sale, Mucormycosis, Risk, Technology, Asos, RNA transfection, Mycosis, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Research, DNA, Safety, University, UNC, Conference, SAD, DPA, DSMB, GLOBE, Therapy, Pharmaceutical industry

Preclinical studies of MAT2203 in Candida auris and mucormycosis (black fungus) scheduled to begin in the second quarter of 2022 to support potential label expansion.

Key Points: 
  • Preclinical studies of MAT2203 in Candida auris and mucormycosis (black fungus) scheduled to begin in the second quarter of 2022 to support potential label expansion.
  • Cash, cash equivalents and marketable securities at December 31, 2021, were approximately $49.6 million, compared to $58.7 million at December 31, 2020.
  • With the support of the Cystic Fibrosis Foundation, MAT2501 is currently undergoing important preclinical studies and commenced a Phase 1 human clinical trial in the fourth quarter of 2021.
  • Matinas BioPharmas product candidates are all in a development stage and are not available for sale or use.

Basilea to become a leading anti-infectives company backed by strong financial results 2021

Retrieved on: 
Tuesday, February 15, 2022
Cryptococcosis, New Drug Application, Patient, Aspergillosis, Webcast, CET, SIX Swiss Exchange, Food, Cancer, FGFR, Board of directors, CHF, Infection, Glioma, PFS, National Medical Products Administration, Center, DCR, Center for Drug Evaluation and Research, IND, FGFR2, NMPA, Adult, Mucormycosis, Acinetobacter baumannii, Isavuconazonium, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, EB1, Progression-free survival, Glioblastoma, SAB, PLK1, ICCA, DXR, TTK, Investigational New Drug, FDA, Population, Mycosis, Pfizer, Board, Communication, USD, Partnership, NDA, Research, MCI, ORR, Plasma protein binding, Pharmaceutical industry

The excellent commercial performance triggered several milestone payments from our partners with a total of approximately CHF 35 million in 2021.

Key Points: 
  • The excellent commercial performance triggered several milestone payments from our partners with a total of approximately CHF 35 million in 2021.
  • The first approval in December 2021 triggered a USD 10 million milestone payment to Basilea.
  • Basilea Pharmaceutica Ltd. will host a conference call and webcast today, Tuesday, February15, 2022, at 4 p.m. (CET), to discuss the Companys financial and operating results and to provide an outlook.
  • Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland.

Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China

Retrieved on: 
Thursday, January 13, 2022
Immunodeficiency, Patient, Research, Mortality, NMPA, Mycosis, SIX Swiss Exchange, I.V. (X Japan song), Basel, Disease, NYSE, Center for Drug Evaluation and Research, Adult, Infection, Mucormycosis, Aspergillosis, Azole, Cancer, Lymphatic system, Center, PFE, National Medical Products Administration, Basilea Pharmaceutica, Communication, Pharmaceutical industry, EU, Isavuconazonium, Pfizer

This is the second approved indication for oral Cresemba in China, after the approval for the treatment of adult patients with invasive mucormycosis, which was received in December 2021.

Key Points: 
  • This is the second approved indication for oral Cresemba in China, after the approval for the treatment of adult patients with invasive mucormycosis, which was received in December 2021.
  • David Veitch, Basileas CEO said: Invasive aspergillosis is the more frequent infection than mucormycosis and we congratulate our partner Pfizer on this second approval of Cresemba in China, thus broadening the range of approved indications.
  • With this approval, patients in China who are suffering from invasive aspergillosis will now have access to a treatment that can help to address their unmet needs.
  • China is a very important commercial market for Cresemba, accounting for approximately 20 percent of global sales for newer antifungals.